A detailed history of Black Rock Inc. transactions in Eyenovia, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 124,799 shares of EYEN stock, worth $9,983. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124,799
Previous 1,575,418 92.08%
Holding current value
$9,983
Previous $1.56 Million 95.32%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.52 - $1.06 $754,321 - $1.54 Million
-1,450,619 Reduced 92.08%
124,799 $73,000
Q1 2024

May 10, 2024

SELL
$0.99 - $2.37 $58,583 - $140,244
-59,175 Reduced 3.62%
1,575,418 $1.56 Million
Q4 2023

Feb 13, 2024

BUY
$1.08 - $2.08 $121,841 - $234,657
112,816 Added 7.41%
1,634,593 $3.4 Million
Q3 2023

Nov 13, 2023

BUY
$1.57 - $2.54 $293,313 - $474,532
186,824 Added 13.99%
1,521,777 $2.53 Million
Q2 2023

Aug 11, 2023

BUY
$2.21 - $5.75 $2.79 Million - $7.25 Million
1,260,966 Added 1704.31%
1,334,953 $3.16 Million
Q1 2023

May 12, 2023

SELL
$1.72 - $3.53 $1,312 - $2,693
-763 Reduced 1.02%
73,987 $261,000
Q4 2022

Feb 13, 2023

BUY
$1.54 - $2.74 $2,830 - $5,036
1,838 Added 2.52%
74,750 $121,000
Q3 2022

Nov 14, 2022

BUY
$1.55 - $2.48 $7,777 - $12,444
5,018 Added 7.39%
72,912 $142,000
Q2 2022

Aug 12, 2022

BUY
$1.71 - $3.26 $13,430 - $25,604
7,854 Added 13.08%
67,894 $132,000
Q1 2022

May 12, 2022

BUY
$2.66 - $3.99 $5,043 - $7,565
1,896 Added 3.26%
60,040 $183,000
Q4 2021

Feb 10, 2022

BUY
$3.5 - $6.58 $8,078 - $15,186
2,308 Added 4.13%
58,144 $233,000
Q3 2021

Nov 09, 2021

SELL
$3.97 - $5.64 $17,543 - $24,923
-4,419 Reduced 7.33%
55,836 $274,000
Q2 2021

Aug 11, 2021

BUY
$4.36 - $5.75 $262,711 - $346,466
60,255 New
60,255 $299,000

Others Institutions Holding EYEN

About EYENOVIA, INC.


  • Ticker EYEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,212,900
  • Market Cap $2.74M
  • Description
  • Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the develop...
More about EYEN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.